Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
A pragmatic evaluation of community-based lymphoedema services for individuals at risk of, or living with, cancer-related lymphoedema.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study examined the long-term effects of standard care lymphoedema treatment, delivered by cancer support centres in community-based settings, on quality of life and self-reported symptom severity among individuals with cancer-related lymphoedema (CRL).
methodsA single-group pre-post pragmatic study design was adopted. Survivors of cancer referred to community-based cancer support centres were recruited. Participants received a minimum of 3 standard care lymphoedema treatment sessions at the centres with a certified lymphoedema clinician at baseline (T1), 1 month (T2) and 6 months (T3), where core treatment strategies included lymphoedema education to enable self-management, skin care and weight management. Assessments of quality of life and symptom severity were conducted at each visit using limb specific versions of the Lymphoedema Quality of Life (LYMQoL) questionnaire (i.e. arm LYMQoL, leg LYMQoL) as applicable for each person, and a researcher-developed tool of self-reported symptom severity.
resultsOne-hundred and twenty survivors of cancer were recruited (mean age (± SD) 59 (± 12y); 90% female). Forty participants (33%) completed the T3 assessment. Linear mixed-model analyses demonstrated significant improvements in arm-CRL QoL (n = 78) and leg-CRL QoL (n = 18) from T1 to T3 (p < 0.05), with small (Cohen's d = 0.24) and large (Cohen's d = 0.85) effect sizes respectively. All 7 self-reported symptom ratings, including pain, swelling and functional restriction, improved from T1-T3.
conclusionStandard care lymphoedema treatment, when delivered in community-based cancer support centres, was associated with improvements in QoL and self-reported symptoms among survivors of cancer with arm and leg lymphoedema at 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.